KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Novavax (NVAX) Interest Expenses (2016 - 2025)

Novavax (NVAX) has 16 years of Interest Expenses data on record, last reported at $5.8 million in Q4 2025.

  • For Q4 2025, Interest Expenses fell 23.22% year-over-year to $5.8 million; the TTM value through Dec 2025 reached $22.5 million, up 12.31%, while the annual FY2025 figure was $22.5 million, 12.31% up from the prior year.
  • Interest Expenses reached $5.8 million in Q4 2025 per NVAX's latest filing, up from $5.5 million in the prior quarter.
  • Across five years, Interest Expenses topped out at $7.6 million in Q4 2024 and bottomed at $2.9 million in Q3 2023.
  • Average Interest Expenses over 5 years is $4.9 million, with a median of $4.9 million recorded in 2021.
  • Peak YoY movement for Interest Expenses: tumbled 49.89% in 2023, then surged 84.24% in 2024.
  • A 5-year view of Interest Expenses shows it stood at $5.1 million in 2021, then dropped by 10.45% to $4.6 million in 2022, then fell by 10.52% to $4.1 million in 2023, then soared by 84.24% to $7.6 million in 2024, then dropped by 23.22% to $5.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Interest Expenses were $5.8 million in Q4 2025, $5.5 million in Q3 2025, and $5.5 million in Q2 2025.